A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer
Colorectal cancer is one of the most common causes of cancer in the Western world. New drugs in the treatment of advanced colorectal cancer, such as irinotecan and oxaliplatin, have substantially increased the cost of treatment. A systematic literature review on the cost (-effectiveness) of pharmaceutical therapies for advanced colorectal cancer was conducted, in which 13 articles were included. The main topics were: orally versus intravenously administered fluoropyrimidine, raltitrexed, irinotecan and oxaliplatin. Additional information was collected on the cost (-effectiveness) of the monoclonal antibodies, cetuximab and bevacizumab. Only five articles had taken the societal perspective, in most articles no data on quality of life was presented, and only two reported the cost per quality-adjusted life year. As only a limited amount of information is available on the cost-effectiveness of pharmaceutical therapies for advanced colorectal cancer, there is a need for more cost-effectiveness studies. These studies are preferably performed by taking a societal perspective and including quality of life outcomes.
|Keywords||Advanced and metastatic colon cancer, Bevacizumab, Capecitabine, Cetuximab, Chemotherapy, Colorectal cancer, Colorectal neoplasm, Cost, Cost-effectiveness, Economics, Fluoropyrimidine, Fluorouracil, Irinotecan, Monoclonal antibody, Oxaliplatin, Raltitrexed, Rectal cancer, Targeted therapy, Uracil plus tegafur|
|Persistent URL||dx.doi.org/10.1517/14656522.214.171.1243, hdl.handle.net/1765/36911|
Krol, H.M., Koopman, M., Uyl-de Groot, C.A., & Punt, C.J.A.. (2007). A systematic review of economic analyses of pharmaceutical therapies for advanced colorectal cancer. Expert Opinion on Pharmacotherapy, 8(9), 1313–1328. doi:10.1517/146565126.96.36.1993